SCHEMBL30717905

SCHEMBL30717905

CC(C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)N[N+](=O)[O-])C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)O)C(C)C

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ F2 P00734 2/20 0.46
▸ GNPAT O15228 1/20 0.44
▸ HRH1 P35367 3/20 0.44
▸ CASP3 P42574 2/20 0.44
▸ CASP7 P55210 1/20 0.44
▸ ACE P12821 1/20 0.44
▸ CASP1 P29466 1/20 0.44
▸ CASP9 P55211 1/20 0.44
▸ TFPI P10646 1/20 0.44
▸ ECE1 P42892 1/20 0.44
▸ CHRNA1 P02708 1/20 0.43
▸ CHRNG P07510 1/20 0.43
▸ CHRNB1 P11230 1/20 0.43
▸ CHRND Q07001 1/20 0.43
▸ SSTR3 P32745 1/20 0.43
▸ NTSR2 O95665 1/20 0.42
▸ NTSR1 P30989 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30717867 0.97 TFPI (0.46) F2HRH1CASP1TFPI
SCHEMBL30717901 0.92 CASP3 (0.47) F2GNPATCASP3CASP7CASP1
SCHEMBL30717846 0.92 GNPAT (0.46) GNPATACEECE1CHRNA1CHRNG
SCHEMBL30717897 0.91 OPRM1 (0.44) F2
SCHEMBL30717848 0.91 OPRM1 (0.44) F2
SCHEMBL30717824 0.90 TFPI (0.57) TFPI
SCHEMBL30717868 0.89 OPRM1 (0.56) F2TFPICHRNA1CHRNGCHRNB1
SCHEMBL31243875 0.88 OPRM1 (0.53) GNPATNTSR2NTSR1
SCHEMBL30717879 0.88 F2 (0.45) F2GNPATCASP1CHRNA1CHRNG
SCHEMBL30717877 0.88 F2 (0.45) F2GNPATCASP1CHRNA1CHRNG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250263393-A1 FAP INHIBITORS SHANGHAI SINOTAU BIOTECH. CO., LTD (CN) 2025-08-21 — — US disclosed
EP-4590664-A1 INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN AND USE THEREOF Shanghai Sinotau Biotech. Co., Ltd (CN) 2025-07-30 — — EP disclosed
WO-2025055942-A1 INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN AND USE THEREOF SHANGHAI SINOTAU BIOTECH. CO., LTD (CN) 2025-03-20 — — WO disclosed
WO-2025055943-A1 INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN AND USE THEREOF SHANGHAI SINOTAU BIOTECH. CO., LTD (CN) 2025-03-20 — — WO disclosed
EP-4511367-A1 FAP INHIBITORS Shanghai Sinotau Biotech. Co., Ltd (CN) 2025-02-26 — — EP disclosed
WO-2024022332-A1 FAP INHIBITORS SHANGHAI SINOTAU BIOTECH. CO., LTD (CN) 2024-02-01 — — WO disclosed
WO-2023202655-A1 FAP INHIBITORS SHANGHAI SINOTAU BIOTECH. CO., LTD (CN) 2023-10-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250263393-A1 FAP INHIBITORS FAP, APC, FIBP F2 508/4885GNPAT 225/4885HRH1 3202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback